Tests short internal radiation for prostate cancer that has returned
Observes internal radiation for returned prostate cancer in adults 18 or older.
Plain-language title generated from the registry record
Registry title: Study on Prostate Salvage Using High-dose-rate Brachytherapy
Key facts
- Where
- Barakaldo, Benidorm, Córdoba, L'Hospitalet de Llobregat, Madrid, Pamplona, San Sebastián, Santander, Valencia, and Vigo, SpainSee the 10 sites
Where in Spain
- Hospital Universitario de CrucesBarakaldo, SpainNot yet recruiting
- Hospital HCB BenidormBenidorm, SpainTaking people
- Hospital Universitario Reina SofiaCórdoba, SpainTaking people
- Instituto Catalán de Oncología L'HospitaletL'Hospitalet de Llobregat, SpainTaking people
- Hospital Universitario Ramón y CajalMadrid, SpainTaking people
- Hospital Universitario de NavarraPamplona, SpainTaking people
- Instituto Oncológico de San Sebastián (Onkologikoa)San Sebastián, SpainNot yet recruiting
- Hospital Universitario Marqués de ValdecillaSantander, SpainTaking people
- Hospital Universitario Y Politecnico La FeValencia, SpainTaking people
- Hospital MeixoeiroVigo, SpainTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic
- Trial code
- NCT07860528
- Record updated
- 9 October 2026
- Original description
A prospective, observational, multicenter study analyzing salvage treatment for prostate cancer-diagnosed via next-generation imaging (choline positron emission tomography (PET)/prostate-specific membrane antigen (PSMA) PET and magnetic resonance imaging (MRI)) and positive biopsy-using two fractions of high-dose-rate (HDR) brachytherapy.Read full original descriptionShow less
Multicenter Prospective Observational Study on Prostate Salvage Using High-dose-rate Brachytherapy
A prospective, observational, multicenter study analyzing salvage treatment for prostate cancer-diagnosed via next-generation imaging (choline positron emission tomography (PET)/prostate-specific membrane antigen (PSMA) PET and magnetic resonance imaging (MRI)) and positive biopsy-using two fractions of high-dose-rate (HDR) brachytherapy.
Inclusion: Age over 18 years; Patients diagnosed with local recurrence confirmed by next-generation imaging and a positive biopsy; Hormone-sensitive patient; Patients whose initial treatment consisted of brachytherapy alone, external beam radiotherapy, or external beam radiotherapy with a prostate brachytherapy boost.
Exclusion: Metastatic disease; Castration-resistant prostate cancer, defined according to EAU (European Association of Urology) guidelines: A patient who progresses despite maintaining testosterone levels within the castration range (testosterone <50 ng/dL or <1.7 nmol/L) and presents with at least one of the following factors: Three consecutive rises in PSA (Prostate-Specific Antigen) levels, measured one week apart, representing two increases of 50% above the nadir, with a PSA level >2; PSA progression despite successive hormonal manipulations; Progression of bone lesions: progression or appearance of two or more bone lesions, or soft-tissue progression according to Response Evaluation Criteria in Solid Tumors (RECIST criteria).